Volume 3, Issue 2, Summer 2024

View Volume 3, Issue 2, Summer 2024

Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies
Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada
Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-line Treatment
High-Risk Myeloma: Definitions and Treatments
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure

Published: 2024-06-27

Full Issue

Articles

Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies

Inna Y. Gong, MD, John Kuruvilla, MD, Michael Crump, MD

5–21
- PDF (en)
- PDF (fr)
Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada

Rena Buckstein, MD, FRCPC

22–29
- PDF (en)
- PDF (fr)
Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-Line Treatment

Lisa Bilston, MD, FRCPC, Kareem Jamani, MD, FRCPC

31–39
- PDF (en)
- PDF (fr)
High-Risk Myeloma: Definitions and Treatments

Rintu Sharma, MD, Karla Alexandra Sánchez Hernández, MD, Guido Lancman, MD, MSc

41–47
- PDF (en)
- PDF (fr)
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure

Sue Robinson, MD, FRCPC

49–53
- PDF (en)
- PDF (fr)